Clarivate PLC (NYSE:CLVT – Get Free Report) has earned a consensus recommendation of “Reduce” from the eight brokerages that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation and five have given a hold recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $3.2167.
CLVT has been the topic of several analyst reports. Wall Street Zen raised Clarivate from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Clarivate in a research note on Wednesday, June 24th.
Get Our Latest Research Report on Clarivate
Institutional Investors Weigh In On Clarivate
Clarivate Stock Down 0.6%
Shares of CLVT opened at $2.58 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.84 and a current ratio of 0.84. Clarivate has a 52 week low of $1.66 and a 52 week high of $4.77. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -12.26 and a beta of 1.38. The business’s fifty day moving average price is $2.41 and its two-hundred day moving average price is $2.58.
Clarivate (NYSE:CLVT – Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.04. The business had revenue of $585.50 million for the quarter, compared to analysts’ expectations of $569.50 million. Clarivate had a positive return on equity of 8.82% and a negative net margin of 5.61%.The firm’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.14 earnings per share. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. On average, analysts predict that Clarivate will post 0.65 earnings per share for the current year.
About Clarivate
Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.
Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.
Further Reading
- Five stocks we like better than Clarivate
- 2 AI Stocks That Could Benefit as AI Moves Beyond the Data Center
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.
